Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADCE-T02 |
| Synonyms | |
| Therapy Description |
ADCE-T02 (AMT-754) is an antibody-drug conjugate (ADC) comprising an antibody that targets Tissue Factor (TF) linked to exatecan, which potentially induces tumor cell killing and inhibits tumor growth (PMID: 41996633). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADCE-T02 | AMT754|AMT 754|AMT-754|ADCET02|ADCE T02 | ADCE-T02 (AMT-754) is an antibody-drug conjugate (ADC) comprising an antibody that targets Tissue Factor (TF) linked to exatecan, which potentially induces tumor cell killing and inhibits tumor growth (PMID: 41996633). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06597721 | Phase I | ADCE-T02 | AMT-754 in Patients With Selected Advanced Solid Tumours | Recruiting | USA | AUS | 0 |